Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd. develops, produces and markets specialty plasma-derived therapeutics and other biopharmaceutical products for rare and serious conditions. News about KMDA commonly covers financial results and guidance, commercial performance of products such as KAMRAB, GLASSIA, HEPAGAM, VARIZIG, WINRHO and CYTOGAM, and supply arrangements for blood-product markets.
Company updates also address plasma collection operations, including FDA-cleared facilities in Texas, product distribution activity, dividend policy and withholding-tax procedures for ordinary-share distributions. Kamada is traded on Nasdaq and the Tel Aviv Stock Exchange.
Kamada Ltd. (NASDAQ: KMDA) announced changes in its Board of Directors. Lilach Asher Topilsky, currently a Director and Senior Partner at FIMI Opportunity Funds, has been appointed Chairman, succeeding Leon Recanati, who remains a Director. Additionally, Ari Shamiss, a veteran hospital executive, has joined the Board. The leadership transition comes as Kamada boasts two FDA-approved products and a promising clinical pipeline, including an immunoglobulin product for COVID-19 under development. FIMI, the largest shareholder, recently made a significant investment in Kamada.
Kamada Ltd. (NASDAQ: KMDA) reported a 6% decrease in Q2 revenues, generating $33.1 million, compared to $35.3 million in 2019. However, H1 2020 revenues rose 7% to $66.4 million. Net income for Q2 was $3.5 million ($0.08/share), down from $6.1 million in Q2 2019. The company is developing a plasma-derived IgG product for COVID-19, with initial batches completed and a clinical trial underway. Cash position stands strong at $104.7 million. The full-year revenue guidance is maintained at $132 million to $137 million.